News Releases

Date Title and Summary Additional Formats
Toggle Summary Peregrine Announces Image Fusion Data From Phase II Cotara Trial; Data To Be Presented at the Meeting of the World Federation of Neuro-Oncology
Peregrine Announces Image Fusion Data From Phase II Cotara Trial; Data To Be Presented at the Meeting of the World Federation of Neuro-Oncology TUSTIN, Calif.--(BW HealthWire)--Nov. 16, 2001--Peregrine Pharmaceuticals Inc. (Nasdaq:PPHM) today announced that image fusion data from its Phase II
View HTML
Toggle Summary Peregrine Pharmaceuticals Announces $5.75 Million Investment From Institutional Investors; Company Director Invests in Offering
Peregrine Pharmaceuticals Announces $5.75 Million Investment From Institutional Investors; Company Director Invests in Offering TUSTIN, Calif.--(BW HealthWire)--Nov. 19, 2001-- Proceeds Will Allow Company to Advance Phase III Clinical Trials and Contract Manufacturing Operations Peregrine
View HTML
Toggle Summary Peregrine Pharmaceuticals Announces It has Agreed Upon the Design of a Phase III Study for Brain Cancer With the FDA; Study Will Treat Patients With Recurrent Glioblastoma Multiforme
Peregrine Pharmaceuticals Announces It has Agreed Upon the Design of a Phase III Study for Brain Cancer With the FDA; Study Will Treat Patients With Recurrent Glioblastoma Multiforme TUSTIN, Calif., Dec 13, 2001 (BW HealthWire) -- Peregrine Pharmaceuticals Inc.
View HTML
Toggle Summary Peregrine Announces Quarterly Conference Call
Peregrine Announces Quarterly Conference Call TUSTIN, Calif., Dec 17, 2001 (BW HealthWire) -- Peregrine Pharmaceuticals Inc. (Nasdaq:PPHM) announced today that it will conduct its quarterly conference call on Thursday, Dec. 20 at 11 a.m. (ET). In order to participate in this call, phone
View HTML
Toggle Summary Peregrine Pharmaceuticals Announces Publication of Data Demonstrating Similar Characteristics of Chimeric and Human TNT Monoclonal Antibodies
Peregrine Pharmaceuticals Announces Publication of Data Demonstrating Similar Characteristics of Chimeric and Human TNT Monoclonal Antibodies TUSTIN, Calif, Dec 17, 2001 (BW HealthWire) -- Study Concludes That Human TNT Antibody Shows Promise for Human Use Peregrine Pharmaceuticals Inc.
View HTML
Toggle Summary Peregrine Pharmaceuticals Announces the Initiation of Human Antibody Generation Against Two Additional Antigen Targets With Xenerex Biosciences
Peregrine Pharmaceuticals Announces the Initiation of Human Antibody Generation Against Two Additional Antigen Targets With Xenerex Biosciences TUSTIN, Calif., Dec 20, 2001 (BW HealthWire) -- Peregrine Pharmaceuticals Inc. (Nasdaq:PPHM) today announced that it has initiated human antibody
View HTML
Toggle Summary Peregrine Pharmaceuticals Announces Formation of Contract Manufacturing Subsidiary Avid Bioservices Inc.
Peregrine Pharmaceuticals Announces Formation of Contract Manufacturing Subsidiary Avid Bioservices Inc. TUSTIN, Calif., Jan 8, 2002 (BW HealthWire) -- Wholly Owned Subsidiary to Provide Biologics Manufacturing and Product Development Services to Biotechnology Industry Peregrine Pharmaceuticals
View HTML
Toggle Summary Peregrine Pharmaceuticals Announces Grant of Patent for New Anti-Cancer Antibodies
Peregrine Pharmaceuticals Announces Grant of Patent for New Anti-Cancer Antibodies TUSTIN, Calif., Jan 29, 2002 (BW HealthWire) -- Peregrine Pharmaceuticals (Nasdaq:PPHM) today announced the issuance of U.S. Patent No. 6,342,219 covering the use of new antibodies for cancer treatment.
View HTML
Toggle Summary Peregrine Pharmaceuticals Announces $2.2 Million Investment From Institutional Investors
Peregrine Pharmaceuticals Announces $2.2 Million Investment From Institutional Investors TUSTIN, Calif., Feb 4, 2002 (BW HealthWire) -- Peregrine Pharmaceuticals (Nasdaq:PPHM) today announced that it has closed an offering for $2.2 million off of the shelf Registration Statement on Form S-3 it
View HTML
Toggle Summary Peregrine and OXiGENE Conclude Arcus Therapeutics LLC Joint Venture; Companies Reacquire Full Rights to Respective Vascular Targeting Technologies
Peregrine and OXiGENE Conclude Arcus Therapeutics LLC Joint Venture; Companies Reacquire Full Rights to Respective Vascular Targeting Technologies TUSTIN, Calif., Feb 28, 2002 (BW HealthWire) -- OXiGENE Inc. (Nasdaq:OXGN)(SSE:OXGN) and Peregrine Pharmaceuticals Inc.
View HTML